CAS
LCTX icon

CTC Alternative Strategies’s Lineage Cell Therapeutics LCTX Stock Holding History

CTC Alternative Strategies’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,307
Closed -$24.2K – 117
2026
Q1 		$24.2K Buy
+15,307
New +$25.8K 0.05% 89

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CTC Alternative Strategies's LCTX Position: Q2 2026 in Review

CTC Alternative Strategies sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 15,307 shares — an estimated $24.2K sold.

CTC Alternative Strategies first reported a position in LCTX in Q1 2026 and held it in 1 quarter. The position peaked at $24.2K in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • CTC Alternative Strategies reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • CTC Alternative Strategies sold 15,307 Lineage Cell Therapeutics shares in Q2 2026, an estimated $24.2K.
  • CTC Alternative Strategies first reported a position in Lineage Cell Therapeutics in Q1 2026 and held it in 1 quarter.
  • CTC Alternative Strategies's Lineage Cell Therapeutics position peaked at $24.2K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on CTC Alternative Strategies's 13F filing for Q2 2026, filed 13 Aug 2026.